Avacta Group (LON:AVCT - Get Free Report) issued its earnings results on Friday. The biotechnology company reported GBX (8.54) (($0.12)) earnings per share for the quarter, Digital Look Earnings reports. Avacta Group had a negative return on equity of 74.00% and a negative net margin of 114.45%.
Avacta Group Price Performance
Avacta Group stock traded up GBX 0.89 ($0.01) during mid-day trading on Monday, hitting GBX 33.30 ($0.45). The stock had a trading volume of 1,253,364 shares, compared to its average volume of 1,768,211. The firm's 50 day moving average is GBX 34.31 and its 200 day moving average is GBX 41.39. The company has a current ratio of 1.29, a quick ratio of 4.96 and a debt-to-equity ratio of 52.53. Avacta Group has a one year low of GBX 26 ($0.35) and a one year high of GBX 86.40 ($1.17). The firm has a market capitalization of £126.51 million, a P/E ratio of -4.29 and a beta of 1.12.
Avacta Group Company Profile
(
Get Free Report)
Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.
Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).
Read More
Before you consider Avacta Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avacta Group wasn't on the list.
While Avacta Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
